EMVision Sets Sight on US With US$10M Keysight Investment
- None.
- None.
Insights
The strategic investment by Keysight Technologies in EMVision represents a significant milestone in the advancement of medical imaging technology, particularly for the diagnosis and treatment of stroke and other neurological conditions. The emu™ brain scanner is poised to disrupt the current imaging paradigm by offering a portable, rapid diagnostic tool that can be used outside of traditional hospital settings. This has the potential to greatly enhance the speed and accessibility of care, particularly in remote or underserved areas where CT and MRI availability is limited.
From a medical research perspective, the acceleration of clinical trials and the expansion of EMVision's production capacity are crucial steps towards validating the efficacy and safety of the emu™ device. The trial data will be instrumental in obtaining regulatory approvals and will be closely scrutinized for its ability to meet stringent medical standards. The investment will also facilitate the development of the first responder device, which could transform emergency care by enabling rapid, on-site neurological assessments. However, it is important to note that until the devices receive regulatory clearance, their impact on healthcare practices remains speculative.
Keysight Technologies' equity stake acquisition in EMVision carries substantial financial implications for both companies. For EMVision, the US$10 million investment provides a fully funded commercial runway, which is critical for a medtech company at this stage of development. It reduces financial risk and underscores investor confidence in EMVision's technology and market potential. The capital infusion is expected to expedite the path to market, which is particularly relevant given the planned market entry next year.
For Keysight, the investment represents a diversification into the medical imaging sector, indicating a strategic move to leverage its technology in new applications. The market capitalization of approximately US$26 billion for Keysight suggests that the investment, while significant, is a calculated risk in the context of its overall portfolio. Investors and analysts will be monitoring the impact of this investment on Keysight's financial performance, as well as any potential synergies that may arise from the partnership.
The partnership between Keysight Technologies and EMVision highlights a growing trend in the healthcare sector towards innovative point-of-care diagnostics. The market for portable diagnostic devices is expanding, driven by the need for more decentralized and rapid healthcare solutions. EMVision's emu™ device is strategically positioned to capitalize on this trend, with the potential to capture a significant share of the market, particularly in stroke care, which is a leading cause of disability and death worldwide.
However, market adoption will depend on several factors, including the outcomes of clinical trials, regulatory approvals and the ability of EMVision to scale production and distribution effectively. It is also essential to consider the competitive landscape, as other companies may be developing similar technologies. The OEM supply partnership and the 'fast sweep' feature give EMVision a competitive edge, but continuous innovation and strategic partnerships will be key to maintaining its market position.
Following a long-standing relationship, Keysight Technologies has acquired a strategic equity stake in EMVision, providing the Aussie Medtech with a fully funded path to market
EMVision from L to R: Robert Tiller - Head of Design, Scott Kirkland - CEO and Managing Director holding the next-Gen first-responder concept, Forough Khandan – Chief Technology Officer and Christian Wight - Head of Regulatory Affairs, with emu™ brain scanner (center). (Photo: Business Wire)
The investment provides EMVision with a fully funded commercial runway for its emu™ device. It accelerates clinical trials, generating essential data supporting the upcoming regulatory approval pathway and adoption in the world’s largest healthcare market. The new capital will also increase the company's production capacity for additional emu™ devices to be used in expanded clinical trials, including leading stroke centres in
With a market capitalisation of approximately
Portable brain imaging for improved patient care
EMVision's emu™ brain scanner is a pioneering advancement in stroke care, intended to provide rapid diagnostic imaging to accelerate the delivery of urgent, life-saving care, particularly in settings where traditional imaging modalities such as CT and MRI are not readily available.
The device is operated at the point of care, with a simple cap placed on the patient's head for quick scans and image generation. It couples safe, ultra-high frequency radio signals with powerful Artificial Intelligence to produce rapid insights directly at the patient’s bedside.
emu™ can be operated by any healthcare professional with minimal training. Targeted for use in intensive care units, stroke and neurology wards, and rural emergency departments, emu™ has the potential to improve survival rates and quality of life after stroke and other neurological events requiring urgent intervention.
The investment follows an original equipment manufacturer (OEM) supply partnership entered into by both companies in 2022, whereby EMVision secured exclusivity in the neuroimaging field for the VNA “fast sweep” feature. This component acts as the ‘brain’ of all EMVision devices, giving the company a substantial competitive advantage.
Scott Kirkland, Founder and CEO at EMVision, said, “Keysight's investment is an endorsement of our mission to improve global stroke outcomes and we're thrilled to embark on this next phase of growth together. Their commitment to being at the frontline of innovation aligns perfectly with EMVision's progress towards making ubiquitous portable brain imaging a reality.”
Huei Sin, Keysight Technologies President, Electronic Industrial Solutions Group, said, “We are delighted to strengthen our relationship with EMVision as we forge ahead in pioneering ground-breaking advancements in medical imaging technology. Keysight's technology leadership, particularly our industry-leading data acquisition speeds, alongside EMVision's brain scanning innovation, strategically positions our companies to spearhead significant developments in cutting-edge imaging solutions.”
EMVision is also developing a first responder device. The backpack-sized scanners will weigh less than 10 kilograms and are intended for deployment via road and air ambulances. It would allow paramedics to scan and send images to specialists from the site of a suspected stroke, meaning patients could be diagnosed and treated more quickly than has previously been possible. Market entry for the emu™ device is planned for next year, with the first responder device to follow.
Under the agreement, Keysight will be issued 7,454,231 new ordinary shares in EMVision at
The emu™️ and the first responder device are neither available for sale nor evaluated by the FDA or other global regulators. The devices may only be used by authorized sites in controlled clinical investigations.
Full details of the announcement can be found at https://emvision.com.au/investors/
About EMVision
EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neuroimaging devices. Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time-sensitive medical emergencies at the point of care. EMVision has offices in
About Keysight Technologies
At Keysight (NYSE: KEYS), we inspire and empower innovators to bring world-changing technologies to life. As an S&P 500 company, we're delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. We're a global innovation leader enabling customers in communications, industrial automation, aerospace and defence, automotive, semiconductor, and general electronics markets to accelerate innovation to connect and secure the world. Learn more at Keysight Newsroom and www.keysight.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229013803/en/
For further information, media or investor enquiries:
Dejan Toracki
Head of Investor Relations
+61 409 340 641
dtoracki@emvision.com.au
Sling & Stone
Media and Communications
+61 2 8073 5390
emvision@slingstone.com
Scott Kirkland
CEO and Managing Director
+61 2 8667 5337
skirkland@emvision.com.au
Source: EMVision
FAQ
What is the significance of the investment by Keysight Technologies in EMVision?
What is the market capitalization of Keysight Technologies?
What is the purpose of the emu™ brain scanner developed by EMVision?
What is the intended use of the first responder device being developed by EMVision?
What percentage shareholding will Keysight Technologies acquire in EMVision?
